Comparative Pharmacology
Head-to-head clinical analysis: ENPRESSE 28 versus GILDESS 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENPRESSE 28 versus GILDESS 1 5 30.
ENPRESSE-28 vs GILDESS 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet orally once daily at the same time each day.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours, allowing once-daily dosing; steady-state achieved within 5-7 days.
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugate (15-20%); biliary/fecal elimination accounts for <5%.
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Category C
Category C
Oral Contraceptive
Oral Contraceptive